Other · 2022
Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin
Healy D, Bahrick A, Bak M, Barbato A, Calabrò RS, Chubak BM, Cosci F, Csoka AB, et al. (2022). Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. International Journal of Risk & Safety in Medicine. doi:10.3233/JRS-210023
An international expert panel proposed diagnostic criteria for post-SSRI sexual dysfunction (PSSD), which commonly involves decreased genital and orgasmic sensation, low sexual desire and erectile dysfunction persisting after the drug is stopped.
Summary
Some people report sexual problems that persist after they stop a serotonin reuptake inhibitor antidepressant, finasteride or isotretinoin. Using data from two published case series and input from a multidisciplinary panel of experts, this paper proposed diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder following serotonin reuptake inhibitors, post-finasteride syndrome and post-retinoid sexual dysfunction.
The authors describe PSSD, post-finasteride syndrome and post-retinoid sexual dysfunction as commonly involving decreased genital and orgasmic sensation, decreased sexual desire and erectile dysfunction, sometimes with non-sexual symptoms such as emotional blunting. The criteria are intended for clinical and research use and are expected to change as evidence develops.
Limitations
These are consensus criteria built from case series, not a study of how often PSSD happens; its incidence is unknown. Several authors are linked to patient-reported adverse-event projects.
What it means for you
Faster ejaculation after stopping an SSRI is not the typical picture of PSSD, which is mainly about reduced sensation, desire and erections. If you notice numbness, loss of pleasure or desire that continues after stopping, tell your doctor.